Ceftolozane/tazobactam: place in therapy

On Behalf Of Isgri-Sita (Italian Study Group On Resistant Infections Of The Società Italiana Terapia Antinfettiva)

Research output: Contribution to journalReview articlepeer-review

Abstract

Introduction: Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing. Areas covered: The place in therapy of C/T is delineated by addressing the following main topics: (i) antimicrobial properties; (ii) pharmacological properties; (iii) results of clinical studies. Expert commentary: C/T is approved for cIAI and cUTI. However, the drug has a special value for clinicians in any kind of infectious localization for two main reasons. The first is that C/T is especially valuable in suspected or documented severe infections due to MDR P. aeruginosa, which is not a rare occurrence in many countries. The second is that C/T may provide an alternative to carbapenems for the treatment of infections caused by ESBL-producers, thus allowing a carbapenem-sparing strategy. Reporting of off-label use is mandatory to increase the body of evidence and the clinicians’ confidence in using it for indications other than cIAI and cUTI.

Original languageEnglish
Pages (from-to)307-320
Number of pages14
JournalExpert Review of Anti-Infective Therapy
Volume16
Issue number4
DOIs
Publication statusPublished - Apr 3 2018

Keywords

  • Antimicrobial resistance
  • carbapenem-sparing
  • ceftolozane
  • Enterobacteriaceae
  • ESBL
  • MDR
  • Pseudomonas
  • tazobactam

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Ceftolozane/tazobactam: place in therapy'. Together they form a unique fingerprint.

Cite this